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Abstract
Background: In the present study, we compared the incidence of hospitalized infection among children with
juvenile idiopathic arthritis (JIA) following initiation of treatment with biologic agents versus methotrexate (MTX).
Methods: We used national Medicaid claims data from 2000 through 2010 to create cohorts of children with
JIA who were new users of tumor necrosis factor inhibitors (TNFi), anakinra, and MTX (without concurrent
biologic agent use) as defined by a 6-month baseline period of nonuse. Because most anakinra users have
systemic juvenile idiopathic arthritis (SJIA), we used claims to identify MTX users who likely had SJIA. Among
TNFi users, concurrent MTX use was a time-varying covariate. The study outcome was a primary hospital
discharge diagnosis of infection. We calculated adjusted hazard ratios (aHRs) to compare infection rates
between biologic agents and MTX.
Results: We identified 3075 new MTX users (160 with SJIA), 2713 new TNFi users, and 247 new anakinra
users. There was no increased risk of infection associated with TNFi monotherapy versus MTX (aHR 1.19, 95 %
CI 0.72–1.94) or with TNFi + MTX combination therapy versus MTX (aHR 1.23, 95 % CI 0.69–2.17). Baseline
high-dose oral glucocorticoid use (≥10 mg/day of prednisone) was associated with infection (aHR 2.03 [95 %
CI 1.21–3.39] versus no oral glucocorticoid). Anakinra was associated with infection versus MTX (aHR 3.53
95 % CI 1.83–6.82), but less so compared with MTX users with SJIA (aHR 2.69, 95 % CI 0.82–8.82).
Conclusions: Neither TNFi monotherapy nor TNFi + MTX combination therapy was significantly associated
with hospitalized infection compared with MTX. Anakinra was significantly associated with infection, but there
was likely residual confounding by disease phenotype.
Background
Biologic agents, especially tumor necrosis factor inhibi-
tors (TNFi), are widely used in the treatment of juvenile
idiopathic arthritis (JIA), and the frequency of their use
continues to increase [1–3]. All therapeutic agents are
associated with risks, and serious infections are the most
commonly occurring serious adverse events in JIA that
are possibly caused by biologic agents. Assessing and
contextualizing the risk of infection due to use of biologic
agents is complicated by the facts that the disease process
of JIA itself likely increases the rate of infection [4] and
that active JIA must be treated with other systemic im-
munosuppression, if not with biologic agents, to prevent
permanent disability [1]. Thus, there is a clear need for
comparative studies of the relative safety of biologic agents
in JIA. Despite the frequent use of biologic agents and the
need for comparative studies, only a few such studies have
been published to date [5, 6].
Among published comparative studies, some do not
suggest a significant difference between infection rates
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associated with TNFi versus methotrexate (MTX) [4, 7],
while others do suggest an increased rate associated with
TNFi [8, 9]. Similar to the situation with studies of
adults with rheumatoid arthritis in which investigators
have reported discrepant results, these differences are
likely attributable to variations in study populations and
study designs [10]. For example, in our previously pub-
lished study in which we reported no increased risk of
infection with TNFi versus MTX, we used a prevalent-
user design rather than a methodologically superior
new-user design that was not feasible, owing to limited
available data at the time [4, 11].
Current JIA treatment recommendations call for the
addition of TNFi to MTX (rather than TNFi monother-
apy) owing to the demonstrated increased effectiveness
of this approach [1]. Nevertheless, many children with
JIA are treated with TNFi monotherapy [2]. Importantly,
the relative safety of combination therapy versus
monotherapy is unclear. The rate of infection associ-
ated with TNFi +MTX combination therapy was not
increased versus TNFi monotherapy in two published
observational studies conducted outside the United
States [8, 12], but this issue has not been fully
assessed in other studies.
There are several non-TNFi biologic agents currently
used for the treatment of JIA, including abatacept, ana-
kinra, canakinumab, and tocilizumab [1, 13]. The relative
risk of infection with these biologic agents in JIA is not
known [5, 6]. The interleukin (IL)-1 inhibitors anakinra
and canakinumab are currently used almost exclusively
to treat systemic juvenile idiopathic arthritis (SJIA) [1, 3,
13, 14]. Limited reports of infections associated with
anakinra suggest a possible increased risk of infection,
but there are no published comparative studies [5]. Im-
portantly, SJIA has a pathogenesis and treatment ap-
proach different from those for the other categories of
JIA, including the more frequent use of systemic gluco-
corticoids (GCs) at higher doses [13, 15, 16]. Very little
is known about the risks of infection associated with
SJIA and its treatment in clinical practice.
In an attempt to address these knowledge gaps, we
used national U.S. Medicaid administrative claims data
to compare rates of hospitalized infection among chil-
dren with JIA who were newly starting biologic agents




We obtained local institutional review board approval.
We conducted this study using Medicaid Analytic eX-
tract (MAX) files from all 50 U.S. states and the District
of Columbia from 2000 through 2010, inclusive. These
were the most recent data available to us at the time of
the study. MAX files contain medical and pharmacy
administrative claims records for low-income children
enrolled in Medicaid (U.S. government medical assistance).
We have previously published studies of JIA using this data
source [4, 17].
Study cohorts
Using pharmacy and infusion claims, we identified pa-
tients who were new users of MTX or biologic agents,
including TNFi (etanercept, adalimumab, infliximab,
golimumab, and certolizumab), abatacept, anakinra,
canakinumab, and tocilizumab. New use was defined by
a 6-month baseline clean period of nonuse during which
the patient had full medical and pharmacy benefits. Add-
itionally, new users of any TNFi had no use of any TNFi
or any other biologic agent during the baseline period
(i.e., those switching biologic agents were excluded).
Only the first observed use of each medication was con-
sidered for new use. Individual patients could have more
than one episode of new use during the study period
(e.g., MTX and then TNFi). New users who had at least
one physician diagnosis code consistent with JIA
(International Classification of Diseases, Ninth Revision
[ICD-9], codes 714, 696.0, 720) before age 16 years and
prior to the new-use prescription fill date (index date)
were included. We excluded patients who had any of the
following at any time prior to the index date: (1) a phys-
ician diagnosis code for JIA when less than 6 months of
age; (2) any physician diagnosis code or hospital dis-
charge diagnosis code for inflammatory bowel disease
(ICD-9 codes 555, 556); (3) any physician diagnosis code
or hospital discharge diagnosis code for malignancy,
organ transplant, or HIV infection; and (4) two or more
physician diagnosis codes or hospital discharge diagnosis
codes for other rheumatologic diseases (systemic lupus
erythematosus and other diffuse connective tissue dis-
eases, vasculitis, sarcoidosis) that were at least 7 days
but more than 183 days apart. New MTX users were ex-
cluded if they used biologic agents at any time prior to
the index date.
In order to better evaluate relative infection rates asso-
ciated with the biologic agents used to treat SJIA, we
attempted to identify patients within the MTX new-user
cohort who were very likely to have SJIA. However,
within ICD-9 there is no specific, reliable physician diag-
nosis code for SJIA. Therefore, we considered new users
of MTX who met any of the following at any time in the
data to have SJIA: (1) any physician diagnosis code or
hospital discharge diagnosis code for macrophage activa-
tion syndrome (ICD-9 code 288.4); (2) any receipt of
anakinra, canakinumab, or rilonacept following receipt
of MTX; (3) any receipt of cyclosporine in the absence
of any physician diagnosis code for uveitis; and (4) any
receipt of thalidomide or lenalidomide. Among children
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with JIA, the development of macrophage activation syn-
drome [18] and use of the selected medications men-
tioned above [1, 13] occur nearly exclusively in children
with SJIA.
Medication exposures
The baseline mean daily GC dose was determined by
summing the total cumulative oral GC dose dispensed
during the 6-month baseline period in milligrams of
prednisone equivalents and dividing by 183 days. Base-
line mean daily GC dose was categorized as none, low
dose (<10 mg of prednisone equivalents per day), and
high dose (≥10 mg of prednisone equivalents per day).
Among new TNFi users, concurrent MTX use was de-
termined on a time-varying basis during study follow-
up. The resultant medication exposure categories were
TNFi monotherapy and TNFi +MTX combination ther-
apy, and patients changed exposure categories during
follow-up on the basis of their treatment received.
Owing to the small number of observed outcomes, we
did not adjust or restrict for concurrent MTX use
among new anakinra users. The concurrent use of cyclo-
sporine was determined on a time-varying basis during
follow-up.
Study follow-up
Follow-up began on the index date. Follow-up was cen-
sored at the first date that any of the following occurred:
(1) prescription for corresponding medication cohort
(MTX or specific biologic agent) not filled within 90 days
of the days supplied by the previous filled prescription or
typical infusion interval (e.g., 56 days for infliximab), (2)
meeting any of the study cohort exclusion criteria, (3) ex-
periencing the primary study outcome of hospitalized in-
fection, or (4) end of the study period. Patients in the new
MTX user cohort were immediately censored if they re-
ceived a biologic agent.
Covariates
Sex, race, and age at index date were determined. The
presence of physician diagnosis codes or hospital dis-
charge diagnosis codes for the comorbid conditions of
psoriasis, diabetes mellitus, and asthma during the 6-
month baseline period was assessed. The occurrence of
infection during the 6-month baseline period was assessed
and assigned to one of three hierarchical levels: none,
nonprimary hospital discharge diagnosis or outpatient
physician diagnosis code, primary hospital discharge diag-
nosis (i.e., a nonprimary discharge or outpatient diagnosis
was not considered in the presence of a primary hospital
discharge diagnosis). Baseline GC use and time-varying
concurrent cyclosporine use during follow-up were mod-
eled as covariates.
Study outcome
The study outcome was a primary hospital discharge diag-
nosis of infection. The outcome included ICD-9 codes
reflecting infections by all organisms (e.g., bacteria,
viruses, fungi). As part of sensitivity analyses, we included
any hospital discharge diagnosis of infection (i.e., primary
and nonprimary hospital discharge diagnoses). The list of
infection ICD-9 codes was adapted from previously vali-
dated lists [19–21].
Analyses
We determined the baseline characteristics of the pa-
tients in each new medication use cohort. We did not
perform statistical tests of the differences between the
cohorts, because individual patients could contribute to
multiple cohorts and the MTX with SJIA cohort was a
subset of the MTX cohort.
We determined crude infection rates for each new
medication user cohort if there were at least ten ob-
served infection outcomes. We considered all TNFi in-
hibitors together as a group compared with MTX in
further analyses.
We used Cox proportional hazards regression models
to compare the incidence of infections between new bio-
logic agent users and new MTX users. For new users of
TNFi, we compared TNFi monotherapy and TNFi +
MTX combination therapy versus MTX within the same
model. For the new users of anakinra, we separately
compared ANA versus MTX and ANA versus MTX
with SJIA. We calculated adjusted hazard ratios (aHRs)
by using multivariable models to adjust for covariates
that were potential confounders of the association
between the medication exposures and the outcome.
Because individual patients could contribute to more
than one new-user cohort, a sandwich variance estima-
tor was applied to account for additional correlations in
the data [22]. To evaluate the possibility of statistical
interaction between oral GC and biologic agent use and
the association with hospitalized infection, we evaluated
separate multivariable hazard models for children with
and without use of oral GCs during the 6-month base-
line period.
We analyzed infection rates among individual TNFi
with etanercept as the referent when there were at least
ten infection outcomes present. We compared patients’
characteristics among the individual TNFi using chi-
square tests. In the multivariable Cox regression models
for the comparison of individual TNFi, we additionally
adjusted for the number of prior biologic agents used
(more than 6 months prior to the index date), and we ig-
nored the concurrent use of MTX.
To evaluate the robustness of our primary results,
we performed the following sensitivity analyses: ex-
panded the outcome definition to include hospital
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discharge diagnosis for infection in any position (i.e.,
included nonprimary discharge diagnoses), decreased
the infection risk window following the days supplied
by the last prescription from 90 days to 30 days, de-
creased the time period used to calculate the baseline
mean daily oral GC dose from 183 days to 60 days,
and censored all follow-up at 6 months following the
index date.
Results
The patients’ characteristics at the time of newly
starting MTX, TNFi, or anakinra are shown in Table 1.
There was an insufficient number of infection out-
comes to report on new users of abatacept, canakinu-
mab, or tocilizumab. The characteristics of new MTX
users with SJIA are also shown. Patients in the MTX
with SJIA subcohort met our definition because of
any use of cyclosporine without uveitis (55 %), future
use of IL-1 inhibitor (51 %), diagnosis of macrophage
activation syndrome (10 %), or any use of thalidomide
or lenalidomide (8 %).
There were clear differences between the cohorts. Spe-
cifically, the TNFi users were older, and the anakinra
users had higher baseline GC use and more frequent pri-
mary hospitalized infections during the baseline period.
The MTX users with SJIA were more similar to the ana-
kinra new users with respect to GC use and baseline in-
fections than were all MTX users.
Table 2 shows the crude infection rates for each of the
medication cohorts. The crude infection rates for all
MTX users, TNFi monotherapy, and TNFi +MTX com-
bination therapy were similar, and ranged from 1.46 to
1.74 infections per 100 person-years. The infection rate
for anakinra users was markedly higher at 8.41 infections
per 100 person-years. The infection rate for MTX with
SJIA was higher than for all MTX users at 2.64 per 100
person-years.
The most commonly observed types of hospitalized
infection overall were pneumonia (19 %), bladder and
kidney (13 %), and cellulitis and abscess (10 %). The
frequency distribution of the types of infection was not
significantly different among new users of MTX, TNFi,
and anakinra (data not shown). We observed two hospi-
talized infections that could be considered opportunistic
infections: one case of herpes zoster in a patient receiving
TNFi and one case of coccidioidal meningitis in a patient
receiving MTX (without prior observed TNFi use).
Table 3 shows the relative hazards of infection in the
analysis of TNFi versus MTX. There was not a signifi-
cantly increased risk of infection associated with TNFi
monotherapy or TNFi +MTX combination therapy
compared with new use of MTX without concurrent or
prior biologic agent use (aHR 1.19 [95 % CI 0.72–1.94]
and aHR 1.23 [95 % CI 0.69–2.17], respectively). In the
hazard models, adjustment for potential confounders
slightly increased the relative hazard associated with
TNFi. This is owing to confounding by patient age; older
Table 1 Characteristics of patients at the time of medication initiation
MTX All TNFi Anakinra MTX with SJIA
Number of patients 3075 2713 247 160
Mean age, years (SD) 9.0 (4.7) 10.9 (4.7) 9.4 (4.8) 7.4 (4.6)
Median age (IQR) 9.0 (5.0–13.0) 11.0 (7.0–15.0) 9.0 (6.0–13.0) 6.5 (3.0–11.0)
Female sex, % 66.0 68.3 64.4 56.9
Asthma, % 8.2 6.1 6.5 7.5
Diabetes mellitus, % 1.1 1.2 1.6 0.6
Psoriasis, % 2.7 3.9 0 8.8
Baseline oral GC dose, %
None 67.1 57.5 22.3 40.0
Low (<10 mg/day) 24.1 29.7 33.6 26.3
High (≥10 mg/day) 8.8 12.9 44.1 33.8
MTX use on index date, % N/A 47.8 37.3 N/A
Cyclosporine use on index date, % 0.4 1.0 3.6 6.9
Baseline infection, %
None 47.7 55.8 45.3 35.0
Nonprimary hospitalized or outpatient 49.6 42.1 47.4 54.4
Primary hospitalized 2.7 2.1 7.3 10.6
Abbreviations: MTX Methotrexate, TNFi Tumor necrosis factor inhibitor, SJIA Systemic juvenile idiopathic arthritis, GC glucocorticoid, mg Milligrams of prednisone
equivalent, N/A Not applicable
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age was associated both with TNFi use and with a lower
baseline risk of infection. A primary hospital discharge
diagnosis of infection during the baseline was strongly
associated with subsequent infection after the index date
compared with no infection during baseline (aHR 3.28
[95 % CI 1.44–7.48]), and this association was less strong
for nonprimary hospital discharge and outpatient diag-
noses (aHR 1.72 [95 % CI 1.12–2.63]). High-dose oral
GC use during the baseline period was associated with
infection compared with no GC use (aHR 2.03 [95 % CI
1.21–3.39]), whereas low-dose GC use was not (aHR
0.86 [95 % CI 0.50–1.46]). Sensitivity analyses that varied
the outcome definition, medication risk window, dur-
ation of the baseline period to assess GC use, and dur-
ation of follow-up did not significantly change these
results (data not shown). Stratified analyses of baseline
GC users and nonusers did not suggest an interaction
between TNFi and GCs with respect to infection (data
not shown).
Table 2 also shows the infection rates observed with
the individual TNFi. There were no infections observed
among new users of certolizumab (0.7 person-years of
observation) or golimumab (3.5 person-years of obs-
ervation). Compared with etanercept, adalimumab use
was associated with an increased risk of infection
(unadjusted HR 1.99 [95 % CI 1.03–3.87]) that persisted
after adjustment for potential confounders (aHR 2.39
[95 % CI 1.21–4.72]). The characteristics of patients
newly initiating etanercept and adalimumab were differ-
ent: 1.0 % of etanercept new users had prior biologic
agent use, compared with 28.2 % of new adalimumab
users (p < 0.0001). Physician diagnosis codes for uveitis
were observed during the 6-month baseline period in
14.0 % of new adalimumab users versus 3.1 % for etaner-
cept (p < 0.0001). Further restricting the analysis to pa-
tients with no prior use of any biologic agent in the
available data did not change the result (aHR 2.36 [95 %
CI 1.18–4.72]). Because adalimumab received its U.S.
Food and Drug Administration (FDA)-approved label for
the treatment of JIA in 2008, we also restricted the com-
parison with etanercept to new medication initiations in
2008 and later. The resulting infection rate associated
with adalimumab appeared more similar to the infection
rate associated with etanercept over the same period
(aHR 1.39 [95 % CI 0.62–3.19]).
Table 4 shows the relative hazards of infection for the
comparison of anakinra and MTX. Anakinra was signifi-
cantly associated with an increased risk of infection
Table 2 Crude infection rates for each medication initiation cohort
Medication exposure Person-years of follow-up Number of infections Infection rate per 100
person-years (95 % CI)
MTX 2668.5 39 1.46 (1.07–2.00)
TNFi monotherapy 2144.0 33 1.54 (1.09–2.17)
TNFi + MTX combination 1094.5 19 1.74 (1.11–2.72)
Anakinra with or without MTX 225.9 19 8.41 (5.36–13.2)
MTX with SJIA 113.7 3 2.64 (0.85–8.18)
Etanercept 2594.0 37 1.43 (1.03–1.97)
Adalimumab 413.2 12 2.90 (1.65–5.11)
Infliximab 227.1 3 1.32 (0.43–4.10)
MTX Methotrexate, TNFi Tumor necrosis factor inhibitor, SJIA Systemic juvenile idiopathic arthritis
Table 3 Relative hazards of infection for tumor necrosis factor inhibitors versus methotrexate




TNFi monotherapy MTX 1.12 (0.70–1.78) 1.19 (0.72–1.94)
TNFi + MTX combination MTX 1.21 (0.69–2.10) 1.23 (0.69–2.17)
Hospitalized infection during baseline No infection during
baseline
3.28 (1.44–7.48)





High-dose oral GC (≥10 mg/day) No oral GC use during
baseline
2.03 (1.21–3.39)
Low-dose oral GC (<10 mg/day) No oral GC use during
baseline
0.86 (0.50–1.46)
TNFi Tumor necrosis factor inhibitor, MTX Methotrexate, GC Glucocorticoid
aMultivariable model included the following variables: new TNFi use, age, sex, asthma, baseline oral GC dose, infection during baseline period
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compared with all MTX users (aHR 3.53 [95 % CI 1.83–
6.82]). High-dose oral GC use was associated with an in-
creased risk of infection compared with no use of GCs
(aHR 2.79 [95 % CI 1.35–5.78]). The increased risk of in-
fection associated with anakinra was somewhat attenu-
ated when the comparator cohort was restricted to
MTX with SJIA (aHR 2.69 [95 % CI 0.82–8.82]).
Discussion
In an analysis of pooled TNFi exposure, we did not ob-
serve a significant increase in hospitalized infection rates
following initiation of TNFi monotherapy or TNFi +
MTX combination therapy compared with initiation of
MTX without prior or concurrent biologic agent use
among children with JIA. These results are consistent
with those of several previously published studies, while
other studies have shown an increased risk of infection
associated with TNFi use. One of the earliest published
studies about comparative rates of serious infections
in clinical practice was a prospective cohort study in
which investigators found no difference in infection
rates between children with JIA receiving etanercept
(n = 103), etanercept plus MTX (n = 294), or MTX
alone (n = 197) [7]. Likewise, we previously published
a study using U.S. Medicaid data reporting no differ-
ence in infection rates between TNFi regardless of
MTX use versus MTX use alone [4], although this
study was limited by its prevalent user design necessi-
tated by limited available data [10, 11].
More recently, reports of serious infections based on
data derived from large, drug-based JIA registries have
been published. Davies et al. analyzed data derived from
the British Society for Paediatric and Adolescent
Rheumatology Etanercept Cohort Study (BSPAR-ETN)
and reported an observed increased rate of “medically
significant” infections among children receiving etaner-
cept versus MTX (aHR 2.13 [95 % CI 1.22–3.74]) [8].
However, the definition of “medically significant” was
based upon the judgment of the treating physician and
potentially biased the results; when the outcome was
limited to infections requiring hospitalization or intra-
venous antibiotics, there was no increased risk of infec-
tion associated with etanercept versus MTX (aHR 1.36
[95 % CI 0.60–3.07]) [8]. Of note, the crude rate of in-
fections requiring hospitalization or intravenous antibi-
otics among children receiving etanercept in that study
(2.2 per 100 person-years) was similar to our observed
rate of hospitalized infection (1.4 per 100 person-years),
whereas the rate of medically significant infections
determined by the treating physician was much higher
(5.5 per 100 person-years) [8]. Additionally, the authors
reported no significant increased risk of infection with
etanercept plus MTX versus etanercept monotherapy,
regardless of the infection outcome definition [8].
Klotsche et al. analyzed data from the German Biologics
in Paediatric Rheumatology (BiKeR) registry and its
follow-up registry, Juvenile arthritis Methotrexate/Bio-
logics long-term Observation (JuMBO), and reported an
Table 4 Relative hazards of infection for anakinra versus methotrexate and anakinra versus methotrexate with systemic juvenile
idiopathic arthritis




Anakinra MTX 5.69 (3.30–9.81) 3.53 (1.83–6.82)
Hospitalized infection during baseline No infection during
baseline
4.81 (1.94–11.9)





High-dose oral GC (≥10 mg/day) No oral GC use during
baseline
2.79 (1.35–5.78)
Low-dose oral GC (<10 mg/day) No oral GC use during
baseline
1.06 (0.54–2.08)
Anakinra MTX with SJIA 3.07 (0.93–10.2) 2.69 (0.82–8.82)
Hospitalized infection during baseline No infection during
baseline
3.10 (0.74–12.9)





High-dose oral GC (≥10 mg/day) No oral GC use during
baseline
2.05 (0.57–7.30)
Low-dose oral GC (<10 mg/day) No oral GC use during
baseline
1.59 (0.41–6.09)
Abbreviations: MTX Methotrexate, SJIA Systemic juvenile idiopathic arthritis, mg Milligrams of prednisone equivalents, GC Glucocorticoid
aMultivariable model included the following variables: new anakinra use, age, sex, asthma, baseline oral GC dose, infection during baseline period, cyclosporine
use (time-varying).
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increased rate of infection with etanercept versus MTX
(adjusted relative risk [aRR] 2.12 [95 % CI 1.08–4.17])
but no increased rate with adalimumab versus MTX
(aRR 0.88 [95 % CI 0.18–4.28]) [9]. Importantly, this
study was not able to adjust for systemic GC use. Also
of note, the crude infection rates for MTX (0.52 per 100
person-years) and etanercept (0.92 per 100 person-years)
in this study were lower than in other published studies
of serious infection in JIA [9], suggesting the possibility
of underreporting of infections by physicians.
We observed that high-dose GC use during the base-
line period was a significant risk factor for subsequent
hospitalized infection. The results of this study showed a
somewhat less extreme risk association with high-dose
GCs (aHR 2.03 [95 % CI 1.21–3.39]) than did our previ-
ously published study (aHR 3.1 [95 % CI 2.0–4.7]) [4].
This different result may be due to the new-user design
employed in the present analysis. In the prior prevalent-
user design, the estimate for GCs may have represented
both the risks attributable to GCs and those attributable
to high disease activity that is frequently associated with
GC use. In the present analysis, some of the confound-
ing by high disease activity was likely diminished by the
new-user design, thus attenuating the risk estimate asso-
ciated with GCs [10, 11]. The authors of the BSPAR-
ETN analyses reported a univariate risk associated with
any baseline GC use that was similar to our study’s re-
sult (HR 2.13 [95 % CI 1.29–3.51]).
We observed a significantly increased risk of infection
with adalimumab compared with etanercept. Although
we restricted this analysis to patients without any use of
biologic agents in the 6-month baseline period, we could
not adequately adjust for the number of prior biologic
agents ever used, because only 20 new users of etaner-
cept (1 %) had any prior use of biologic agents, com-
pared with 28 % of adalimumab users. Therefore, new
users of adalimumab likely had more refractory disease
and a potentially resultant increased baseline risk of in-
fection. When we restricted the analysis to patients with-
out any observed prior use of biologic agents, we
obtained the same result, but the identification of any
prior biologic agent use may have been limited by left
censoring. Additionally, we observed only 12 infections
among the adalimumab users, and therefore our results
may be susceptible to random chance. Another consider-
ation is that etanercept was available for several years
prior to the availability of adalimumab, likely influencing
prescribing patterns for both medications. When we re-
stricted our analysis to the period after adalimumab re-
ceived its FDA-approved label for JIA, the infection rates
appeared more similar, but the estimate was imprecise
because few infection outcomes were observed.
Interestingly, the authors of the BiKeR/JuMBO ana-
lyses reported the opposite observation. In that study,
adalimumab was associated with fewer infections than
etanercept (aRR 0.88 [95 % CI 0.18–4.28]), although
there were only two infection outcomes in the adalimu-
mab cohort with a resultant wide 95 % CI. Another im-
portant consideration when comparing these TNFi is the
fact that adalimumab is frequently prescribed for the
treatment of anterior uveitis associated with JIA and eta-
nercept is not [14, 23]. There may be differential base-
line infection risks based upon the presence of active
uveitis versus synovitis. In our study, we were not able
to reliably determine whether patients received TNFi for
the treatment of active uveitis versus synovitis, but com-
pared with etanercept users, the new users of adalimu-
mab were much more likely to have diagnosis codes for
uveitis during the baseline period.
In analyzing the largest published cohort, to our
knowledge, of children with JIA initiating anakinra, we
observed a significantly increased risk of infection com-
pared with MTX, even with adjustment for GC dose
during the baseline period. It can be assumed that most
children receiving anakinra had SJIA [1, 3, 13, 14], but
this could not be determined with certainty on the basis
of our data, as we did not have access to medical re-
cords. When we restricted the new MTX user compara-
tors to those very likely to have SJIA, the relative risk
associated with anakinra was partially attenuated but still
elevated. It must be noted that our definition of SJIA
was limited by the lack of clinical data. Our definition
could not be validated with the data available, and the
sensitivity and specificity of the definition are unknown.
For example, it is possible that a small minority of MTX
users with SJIA received oral cyclosporine for treatment
of skin psoriasis rather than SJIA, as suggested by the in-
creased proportion of children with psoriasis in this sub-
cohort compared with MTX (2.7 % versus 8.8 %).
Additionally, we observed only three infections among
the MTX users with SJIA; therefore, our results may be
susceptible to random chance.
Previously reported rates of infection associated with
anakinra are highly variable. On one hand, in one case
series of 33 patients receiving anakinra [24] and one pro-
spective cohort study of 20 newly diagnosed patients re-
ceiving anakinra without concurrent GCs [25], researchers
reported no observed serious infections. On the other
hand, investigators in a different published case series of
46 patients receiving anakinra as part of their initial treat-
ment regimen reported 3 serious infections (approximate
rate of 6 serious infections per 100 person-years) [26]. In
addition, researchers in a clinical trial with an open-label
extension period in which 22 total patients received ana-
kinra reported 4 serious infections (approximate rate of 25
serious infections per 100 person-years) [27]. A different
clinical trial of anakinra for polyarticular course JIA re-
ported 2 serious infections among 86 total patients, but an
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approximate infection rate cannot be determined on the
basis of the data published [28]. Similarly, published
clinical trial data derived from studies of the other
commercially available IL-1 inhibitors (canakinumab
and rilonacept) do not allow for calculation of
approximate serious infection rates for comparison
[29, 30]. Looking beyond evidence in JIA, the authors
of a published meta-analysis of randomized clinical
trials of anakinra for adults with rheumatoid arthritis
demonstrated a significantly increased risk of infec-
tion compared with placebo (odds ratio 3.40 [95 % CI
1.11–10.46]) [31].
Very little is known about background infection rates
among children with SJIA compared with other categor-
ies of JIA, but it is plausible that the infection risk may
be much greater. We controlled for baseline GC use to
the extent possible in our study and still observed an in-
creased risk associated with anakinra. One potential
source of published evidence about the possibility of a
differential baseline infection risk is a comparison of the
infection rates in the two recently published clinical tri-
als for tocilizumab, one for polyarticular JIA and the
other for SJIA. In the polyarticular JIA trial, the serious
infection rate was approximately 6.7 per 100 person-
years during the open-label run-in portion of the trial
and 3.1 per 100 person-years during the remainder of
the study [32]. In the SJIA trial, the rate of serious infec-
tion was approximately 17 per 100 person-years [33],
suggesting an increased risk of infection in children with
SJIA that is independent of biologic agent use. Of
course, these studies are not directly comparable, be-
cause the patients in the SJIA study received higher
doses of tocilizumab and GCs. We attempted to control
for the effects of SJIA by restricting the MTX compara-
tor group to children with likely SJIA, but residual con-
founding by disease severity and disease activity was
likely present, as we could not reliably assess these fac-
tors using administrative claims data.
It is notable that our study was limited by the data
source. We used a new-user design to control for arthritis
disease activity at the time of newly starting a medication
[11] because disease activity is known to be associated
with an increased risk of infection in adults with rheuma-
toid arthritis [34]. Nevertheless, administrative claims do
not contain clinical data, and residual confounding by dis-
ease activity was possible in our results and could not be
further evaluated in this study.
Conclusions
We did not observe an increased risk of infection with
TNFi monotherapy or TNFi +MTX combination therapy
compared with MTX alone. Recent infection and high-dose
oral GC use were important risk factors for hospitalized in-
fection. Adalimumab was associated with an increased risk
of infection compared with etanercept, but this result may
be confounded by disease severity. Anakinra was associated
with increased risk of infection compared with MTX. More
studies are needed to elucidate the risks of infection associ-
ated with SJIA and its treatment.
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